Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Cited In for PubMed (Select 17761550)

1.

Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system.

Lathuilière A, Mach N, Schneider BL.

Int J Mol Sci. 2015 May 8;16(5):10578-600. doi: 10.3390/ijms160510578. Review.

2.

Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: "real life" long-term outcome.

Beykin G, Grunin M, Averbukh E, Banin E, Hemo Y, Chowers I.

BMC Ophthalmol. 2015 Apr 11;15:39. doi: 10.1186/s12886-015-0019-x.

3.

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles.

de la Hera B, Urcelay E, Brassat D, Chan A, Vidal-Jordana A, Salmen A, Villar LM, Alvarez-Cermeño JC, Izquierdo G, Fernández O, Oliver B, Saiz A, Ara JR, Vigo AG, Arroyo R, Meca V, Malhotra S, Fissolo N, Horga A, Montalban X, Comabella M.

Neurol Neuroimmunol Neuroinflamm. 2014 Dec 11;1(4):e47. doi: 10.1212/NXI.0000000000000047. eCollection 2014 Dec.

4.

Biomarkers of therapeutic response in multiple sclerosis: current status.

Harris VK, Sadiq SA.

Mol Diagn Ther. 2014 Dec;18(6):605-17. doi: 10.1007/s40291-014-0117-0. Review.

5.

Benefits versus risks of latest therapies in multiple sclerosis: a perspective review.

Ontaneda D, Di Capua D.

Ther Adv Drug Saf. 2012 Dec;3(6):291-303. doi: 10.1177/2042098612462599. Review.

6.

Immunogenicity and other problems associated with the use of biopharmaceuticals.

Tovey MG, Lallemand C.

Ther Adv Drug Saf. 2011 Jun;2(3):113-28. doi: 10.1177/2042098611406318. Review.

7.

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.

O'Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, Hauswirth K, Cristiano LM, Forrestal F, Duda P.

Neurology. 2014 Jul 1;83(1):78-86. doi: 10.1212/WNL.0000000000000541. Epub 2014 Jun 4. Erratum in: Neurology. 2014 Aug 19;83(8):773.

8.

Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.

Hoepner R, Faissner S, Salmen A, Gold R, Chan A.

J Cent Nerv Syst Dis. 2014 Apr 28;6:41-9. doi: 10.4137/JCNSD.S14049. eCollection 2014. Review.

9.

Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.

Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S; American Association of Pharmaceutical Scientists.

AAPS J. 2014 Jul;16(4):658-73. doi: 10.1208/s12248-014-9599-2. Epub 2014 Apr 24.

10.

Clinical utility of glatiramer acetate in the management of relapse frequency in multiple sclerosis.

Fernández O.

J Cent Nerv Syst Dis. 2012 Aug 29;4:117-33. doi: 10.4137/JCNSD.S8755. Print 2012.

11.

Best practice in the use of natalizumab in multiple sclerosis.

Fernández O.

Ther Adv Neurol Disord. 2013 Mar;6(2):69-79. doi: 10.1177/1756285612470401.

12.

Glatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?

Jalilian B, Einarsson HB, Vorup-Jensen T.

Int J Mol Sci. 2012 Nov 9;13(11):14579-605. doi: 10.3390/ijms131114579. Review.

13.

Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics.

Zhou L, Hoofring SA, Wu Y, Vu T, Ma P, Swanson SJ, Chirmule N, Starcevic M.

AAPS J. 2013 Jan;15(1):30-40. doi: 10.1208/s12248-012-9408-8. Epub 2012 Oct 9.

14.

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.

Harrer A, Pilz G, Einhaeupl M, Oppermann K, Hitzl W, Wipfler P, Sellner J, Golaszewski S, Afazel S, Haschke-Becher E, Trinka E, Kraus J.

PLoS One. 2012;7(2):e31784. doi: 10.1371/journal.pone.0031784. Epub 2012 Feb 20.

15.

Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.

Bugelski PJ, Martin PL.

Br J Pharmacol. 2012 Jun;166(3):823-46. doi: 10.1111/j.1476-5381.2011.01811.x. Review.

16.

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab.

Patti F, Pappalardo A.

Clinicoecon Outcomes Res. 2009;1:45-51. Epub 2009 Aug 21.

17.

Treatment of multiple sclerosis.

Pandit L, Murthy JM.

Ann Indian Acad Neurol. 2011 Jul;14(Suppl 1):S65-9. doi: 10.4103/0972-2327.83094. No abstract available.

18.

Development of oral immunomodulatory agents in the management of multiple sclerosis.

Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA.

Drug Des Devel Ther. 2011;5:255-74. doi: 10.2147/DDDT.S10498. Epub 2011 May 10. Review.

19.

Natalizumab in the treatment of multiple sclerosis.

Yaldizli O, Putzki N.

Ther Adv Neurol Disord. 2009 Mar;2(2):115-28. doi: 10.1177/1756285608101861.

20.

Natalizumab in pediatric multiple sclerosis patients.

Yeh EA, Weinstock-Guttman B.

Ther Adv Neurol Disord. 2010 Sep;3(5):293-9. doi: 10.1177/1756285610381526.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk